drugset
drugset / Trial / NCT05323981

Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection

NCT05323981 ↗

Phase 1 Completed 180 enrolled BioRay Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the bioequivalence of HS627(2 specifications) with PERJETA in a single intravenous administration in healthy subjects

Timeline

Start
2022-04-11
Primary completion
2022-10-09
Completion
2022-10-09

Drugs

EvaluationDrugModalityDoseRoute
Subject HS627 Monoclonal antibody 420 mg Intravenous
Comparator Pertuzumab Monoclonal antibody 420 mg Intravenous

Indications

No indication recorded.